TIDMRENX

RNS Number : 4032O

Renalytix PLC

08 October 2021

Renalytix plc

("Renalytix" or the "Company")

Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21

LONDON and SALT LAKE CITY, October 8, 2021 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (EDT) / 1:30 p.m. (BST).

Conference Call Details:

US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551

US/Canada Participant International Dial-In Number: (914) 987-7290

United Kingdom International Dial-In Number: 0800 0288 438

United Kingdom Local Dial-In Number: 0203 1070 289

Conference ID:6364722

   Webcast Registration link:   https://edge.media-server.com/mmc/p/r4ezp7bk

For further information, please contact:

 
Renalytix plc                                            www.renalytix.com 
James McCullough, CEO                                      Via Walbrook PR 
 
Stifel (Nominated Adviser, Joint Broker                 Tel: 020 7710 7600 
 ) 
Alex Price / Nicholas Moore 
 
Investec Bank plc (Joint Broker)                        Tel: 020 7597 4000 
Gary Clarence / Daniel Adams 
 
Walbrook PR Limited         Tel: 020 7933 8780 or renalytix@walbrookpr.com 
Paul McManus / Lianne Cawthorne             Mob: 07980 541 893 / 07584 391 
                                                                       303

CapComm Partners Tel: 415-389-6400 or investors@renalytix.com

Peter DeNardo

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis(TM) for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX(TM), has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com ). For more information, visit www.renalytix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORUPGQCUUPGGWM

(END) Dow Jones Newswires

October 08, 2021 02:00 ET (06:00 GMT)

Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Renalytix.
Renalytix (LSE:RENX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Renalytix.